<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ZALEPLON</span><br/>(zal'ep-lon)<br/><span class="topboxtradename">Sonata<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anxiolytic</span>; <span class="classification">sedative-hypnotic</span>; <span class="classification">nonbenzodiazepine</span><br/><b>Prototype: </b>Zolpidem<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg capsules.</p>
<h1><a name="action">Actions</a></h1>
<p>Short acting nonbenzodiazepine with sedative-hypnotic, muscle relaxant, and anticonvulsant activity.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectiveness is indicated by less difficulty in initially falling asleep. Preserves deep sleep (stage 3 through stage 4)
         at hypnotic dose with minimal-to-absent rebound insomnia when discontinued.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term treatment of insomnia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to zaleplon.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concurrent use of other CNS depressants (e.g., benzodiazepines, alcohol); history of drug abuse; hepatic or renal impairment;
         pulmonary disease; pregnancy (category C); lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Insomnia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg h.s. (max: 20 mg h.s.)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 5 mg h.s. (max: 10 mg h.s.)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give immediately before bedtime; not while patient is still ambulating.</li>
<li>Give lower dose of 5 mg to older adult or debilitated patients.</li>
<li>Store at 20°25° C (68°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Asthenia, fever, <span class="speceff-common">headache,</span> migraine, myalgia, back pain. <span class="typehead">CNS:</span> Amnesia, dizziness, paresthesia, somnolence, tremor, vertigo, depression, hypertonia, nervousness, difficulty concentrating. <span class="typehead">GI:</span> Abdominal pain, dyspepsia, nausea, constipation, dry mouth. <span class="typehead">Respiratory:</span> Bronchitis. <span class="typehead">Skin:</span> Pruritus, rash. <span class="typehead">Special Senses:</span> Eye pain, hyperacusis, conjunctivitis. <span class="typehead">Urogenital:</span> Dysmenorrhea. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> <b> Alcohol,</b> <b>imipramine,</b> <b>thioridazine</b> may cause additive CNS impairment; <b>rifampin</b> increases metabolism of <b>zaleplon;</b> <b>cimetidine</b> increases serum levels of <b>zaleplon.</b> <span class="typehead">Herbal:</span> <b>Valerian,</b> <b>melatonin</b> may produce additive sedative effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly and completely absorbed, 30% reaches systemic circulation. <span class="typehead">Onset:</span> 1520 min. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Duration:</span> 34 h. <span class="typehead">Distribution:</span> 60% protein bound.  <span class="typehead">Metabolism:</span> Extensively metabolized in liver to inactive metabolites. CYP3A4 is one of its metabolic pathways. <span class="typehead">Elimination:</span> 70% excreted in urine, 17% in feces. <span class="typehead">Half-Life:</span> 1 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor behavior and notify physician for significant changes. Use extra caution with preexisting clinical depression.</li>
<li>Provide safe environment and monitor ambulation after drug is ingested.</li>
<li>Monitor respiratory status with preexisting compromised pulmonary function.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Exercise caution when walking; avoid all hazardous activities after taking zaleplon.</li>
<li>Do not take in combination with alcohol or any other sleep medication.</li>
<li> 							Note: Exhibits altered effectiveness if taken with/immediately after high fat meal. 						</li>
<li>Do not use longer than 23 wk.</li>
<li>Expect possible mild/brief rebound insomnia after discontinuing regimen.</li>
<li>Report use of OTC medications to physician (e.g., cimetidine).</li>
<li>Report pregnancy to physician immediately.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>